Three drugs together for kidney cancer that has spread to the brain
Original title: A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a mid-stage test in people, and it is not yet care you can get from your own doctor.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests three cancer drugs given together for kidney cancer that has spread to the brain.
Who this trial is for. This trial is for people with kidney cancer that has spread to the brain. The spots in the brain must not have been treated yet. It tests three drugs given together: nivolumab, ipilimumab, and cabozantinib.
Where it stands. This trial has not reported results. The description does not say what it will measure. The answer is not in yet.
What this means, and what it doesn't
What it could mean: Researchers are looking at a new way to treat brain spots from kidney cancer before other treatment. If you or someone you care for has this, you might ask the care team about this trial. The trial team decides who can join.
What it doesn't mean: A trial is a test, not a proven treatment. Being in a trial does not mean it will help you. This is not a cure, and no one knows yet if this mix of drugs works.
Source: ClinicalTrials.gov, September 18, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.